Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01871714
Other study ID # ECP-014
Secondary ID
Status Completed
Phase N/A
First received June 3, 2013
Last updated November 25, 2013
Start date May 2013
Est. completion date September 2013

Study information

Verified date November 2013
Source Edimer Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

The current study design incorporates two previously developed, non-invasive approaches to characterize the phenotype of individuals affected with XLHED.


Description:

The current study design incorporates two previously developed, non-invasive approaches to characterize the phenotype of individuals affected with XLHED. Facial 3-dimensional (3D) imaging will be created from white-field morphometric scanning (Hammond, 2004. The 3D facial photographs collected from males (ages 4 years and up) will be used to develop a non-invasive screening tool, which could enable detection of craniofacial signs of XLHED in the newborn period. 3D facial profiling has been reported to be effective in identifying HED (Dellavia et al., 2008), but the technology does not yet meet the ease-of-use criteria for a universal screening tool.

Standard 2-dimensional (2D) frontal and lateral facial photographs will be taken of the same XLHED-affected male subjects as well as of adult females (ages 18-45 yrs) at risk for being XLHED carriers and unaffected adult female controls. The 2D facial photographs will serve a dual purpose; the first being to beta-test a previously developed algorithm to identify males affected with XLHED (Automatic Phenotype Identification of XLHED Patients Final Report, December 25, 2012, unpublished), and the second to adapt the facial recognition algorithm to identify female carriers of XLHED.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 2013
Est. primary completion date July 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 4 Years and older
Eligibility Inclusion Criteria:

1. Females of original gender of age 18-45 years who are registered and attending the 2013 NFED Family Conference. This will include those at risk for XLHED and controls

2. XLHED-affected males of original gender of age 4 yrs and up who are registered and attending the 2013 NFED Family Conference

3. Provide informed consent/assent

Exclusion Criteria:

1. Subjects who are not able or are not willing to comply with the procedures of this protocol

2. Subjects with any major medical problem that will prevent them from participating in this study

3. Male subjects who participated in the prior study ECP-003 sponsored by Edimer Pharmaceuticals Inc. in May 2011 in San Francisco, CA

4. Males at risk for XLHED with prior genetic testing that did not reveal an EDA mutation

Study Design

N/A


Related Conditions & MeSH terms


Locations

Country Name City State
United States Omni Houston Hotel Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Edimer Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls using a medical questionnaire Study day 1 No
Primary To test and refine a computer algorithm for facial recognition of XLHED To test and refine a computer algorithm for facial recognition of XLHED based on 2D facial photographs obtained from subjects at risk for XLHED and controls Study day 1 No
Primary To evaluate 3-dimensional facial imaging technology for mapping craniofacial development in XLHED males To evaluate 3-dimensional facial imaging technology for mapping craniofacial development in XLHED males Study day 1 No
Primary To test for the presence of genetic mutations in subjects at risk for XLHED To test for the presence of genetic mutations in subjects at risk for XLHED who lack prior genetic diagnosis Study day 1 No
Primary To test the validity of a using saliva samples for genetic testing To test the validity of a using saliva samples for genetic testing buy simultaneously perform genetic testing on blood and salvia and comparing the mutations identified Study day 1 No

External Links